FDA's Consulting Role Would Not Compromise Independence - Lumpkin
Executive Summary
FDA independence and objectivity would not be compromised by an expanded consulting role, FDA Deputy Director for Review Management Murray Lumpkin, MD, said at a Tufts Center for the Study of Drug Development meeting in Philadelphia Jan. 27.